Skip to main content

HHealthcare stocks turned very mixed on Friday afternoon, with the NYSE Health Care Index up 0.1% and the ETF Health Care Select Sector SPDR (XLV) down 0.1%.

The Nasdaq Biotechnology Index was down 0.6%.

In company news, Xeris Biopharma (XERS) rose 20% after it announced Thursday evening the approval by the US Food and Drug Administration of its synthetic cortisol inhibitor Recorlev to treat endogenous hypercortisolemia in patients adults with Cushing’s syndrome. The company plans to begin commercial sales in the first three months of 2022.

Nutriband (NTRB) nearly tripled in value, recently climbing nearly 165%, after saying its Aversa deterrent technology had received a full patent from the South Korean Intellectual Property Office.

Vir Biotechnology (VIR) added 3.4% after the company said new preclinical data showed its monoclonal antibody sotrovimab retains neutralizing activity in vitro against all known variants of COVID-19, including omicron. Vir developed sotrovimab in partnership with GlaxoSmithKline (GSK) and received emergency use authorization to treat mild to moderate COVID-19 from the United States Food and Drug Administration.

Sintx Technologies (SINT) fell 2.7% after the medical device company announced Scientific Director Bryan McEntire will retire at the end of the year, becoming Scientific Director Emeritus. Ryan Bock, currently director of research and development at Sintx, will succeed McEntire, the company said.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.